Stocktoria
NewcelX Ltd. NCEL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-01-29
NewcelX Ltd. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $1.1M | $992,000 | $1.6M | $9.0M | $5.9M |
| Operating income | -$2.6M | -$2.1M | -$3.0M | -$15.5M | -$11.9M |
| Interest expense | — | — | $119,920 | $95,211 | $48,100 |
| Net income | -$8.3M | -$7.2M | -$3.3M | -$16.5M | -$11.9M |
| EPS (diluted) | $2.16 | $2.43 | $1.13 | $-33.52 | $-1.00 |
| Operating cash flow | -$2.8M | -$1.1M | -$3.4M | -$13.9M | -$14.9M |
| Free cash flow | -$2.8M | -$1.1M | -$3.5M | — | -$15.0M |
| Cash & equivalents | $2.2M | $650,000 | $1.1M | $8.9M | $5.4M |
| Total assets | $11.4M | $903,000 | $1.8M | $9.3M | $5.8M |
| Total liabilities | $4.2M | $8.9M | $10.7M | $6.0M | $5.2M |
| Shareholders' equity | $7.2M | -$8.0M | -$1.2M | $111,000 | $542,388 |
Source: SEC EDGAR filings · CIK 0001783036 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.